The effects of chronic oral treatment with the 5-hydroxytryptamine (serotonin) receptor blocking agent ketanserin (17 mg/100 g dry food) on blood pressure, heart weight, peripheral vascular reactivity, baroreceptor sensitivity, central cardiovascular reactivity and central catecholamine turnover were investigated in the spontaneously hypertensive rat. Blood pressure measurements were performed in conscious rats 24 h after insertion of catheters. After 6 weeks treatment basal blood pressure was reduced (16%) compared to control rats (given identical food, except for ketanserin). Both heart weight and body weight were reduced (both to 93% of control values) leaving heart weight/body weight ratio unchanged. Pressor responses to phenylephrine and depressor responses to isoprenaline (after pretreatment with reserpine and atropin) were not different while the blood pressure increase to 5-hydroxytryptamine was inhibited, indicating that after 6 weeks treatment the blood pressure reduction is not directly related to α-adrenoceptor blockade. Cardiovascular response to stress (jet air), baroreceptor sensitivity (bradycardia to phenylephrine) and central catecholamine synthesis rates (accumulation of 5-hydroxytryptophan and dihydroxyphenylalanine after synthesis inhibition) were unchanged supporting earlier evidence that central mechanisms probably do not contribute to the hypotensive effects of ketanserin.
This is a preview of subscription content, log in via an institution to check access.
Access this article Subscribe and saveSpringer+ Basic
€34.99 /Month
Price includes VAT (Germany)
Instant access to the full article PDF.
Similar content being viewed by others Explore related subjectsDiscover the latest articles and news from researchers in related subjects, suggested using machine learning. ReferencesAntonaccio MJ, Robson RD, Povalski HS (1973) Modification by antihypertensive drugs of reflex circulatory responses induced by vertical tilting or bilateral carotid occlusion. Eur J Pharmacol 22:23–31
Antonaccio MJ, Kelly E, Halley J (1975) Centrally mediated hypotension and bradycardia by methysergide in anaesthetized dogs. Eur J Pharmacol 33:107–117
Atack CV, Magnusson T (1978) A procedure for the isolation of noradrenaline (together with adrenaline), dopamine, 5-hydroxytryptamine and histamine from the same tissue sample using a single strongly acidic cation exchange resin. Acta Pharmacol Toxicol 42:35–57
Carlsson A, Davies JN, Kehr W, Lindqvist M, Atack CV (1972) Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in the brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch Pharmacol 275:153–168
Clark DWJ (1971) Effects of immunosympathectomy on development of high blood pressure in genetically hypertensive rats. Circ Res 28:330–336
Collins MG, Vanhoutte PM (1977) Vascular reactivity of isolated perfused kidneys from male and female spontaneously hypertensive rats. Circ Res 41:759–767
DeClerk FF, Herman AG (1983) 5-hydroxytryptamine and platelet aggregation. Fed Proc 42:228–232
DeCree, Leempoels J, DeCock W, Geukens H, Verhaegen H (1981) The antihypertensive effect of a pure and selective serotonin-receptor blocking agent (R41468) in elderly patients. Angiology 32:137–144
Folkow B, Hallbäck M, Lundgren Y, Weiss L (1971) The effect of intensive treatment with hypotensive drugs on structural design of the resistance vessels in spontaneously hypertensive rats. Acta Physiol Scand 8:280–282
Fouzard JR (1982) Mechanism of the hypotensive effect of ketanserin. J Cardiovasc Pharmacol 4:829–838
Hallbäck M (1975) Consequences of social isolation on blood pressure, cardiovascular reactivity and design in spontaneously hypertensive rats. Acta Physiol Scand 93:455–465
Hallbäck M, Folkow B (1974) Cardiovascular responses to acute mental “stress” in spontaneously hypertensive rats. Acta Physiol Scand 90:684–698
Haeusler G (1974) Clonidine-induced inhibition of sympathetic nerve activity: No indication for a central presynaptic or an indirect sympathicomimetic mode of action. Naunyn-Schmiedeberg's Arch Pharmacol 286:97–111
Hedner T, Persson B, Berglund G (1983a) Ketanserin, a novel 5-hydroxytryptamine antagonist: Monotherapy in essential hypertension. Br J Clin Pharmacol 16:121–125
Hedner T, Persson B, Berglund G (1983b) Experience with ketanserin, a serotonin (S2) antagonist, in longterm treatment of essential hypertension. Clin Exp Hypertension A 6(3):743–751
Kalkman HO, Timmermans PBMWM, van Zwieten PA (1982) Characterization of the antihypertensive properties of ketanserin (R 41468) in rats. J Pharm Exp Ther 222:227–231
Kehr W, Carlsson A, Lindqvist M (1972) A method for the determination of 3,4-hydroxyphenylalanine (DOPA) in brain. Naunyn-Schmiedeberg's Arch Pharmacol 274:273–280
Leysen JE, Awouters F, Kennis L, Lauderon PM, Vandenberk J, Janssen PAJ (1981) Receptor binding profile of R 41468, a novel antagonist at 5-HT2 receptors. Life Sci 28:1015–1022
Larson P, Lung B, Hallbäck-Nordlander M (1982) Baroreceptor control during antihypertensive treatment with felodipine in SHR. Acta Physiol Scand, suppl 508, 43
Lundin S, Thorén P (1982) Renal function and sympathetic activity during mental stress in normotensive and spontaneously hypertensive rats. Acta Physiol Scand 115:115–124
Okamoto K (1972) Spontaneous hypertension. Igaku Shoin Ltd, Tokyo
Persson B, Hedner T, Berglund G (1983) Ketanserin in essential hypertension. Effects during rest and exercise. Eur J Clin Pharmacol 25:307–312
Persson B, Hedner T, Henning M (1982) Cardiovascular effects in the rat of ketanserin, a novel 5-hydroxytryptamine receptor blocking agent. J Pharm Pharmacol 34:442–445
Schneider E, Felix W, Thile U (1983) Central cardiovascular effects of ketanserin, a selctive 5-HT2-antagonist. Abstract to First European Meeting of Hypertension, Milan, Italy, p 393
Stone CA, Ross CA, Wenger HC, Ludden DT, Blessing JA, Totaro JA, Porter CC (1962) Effect of a-methyl-3,4-dihydroxyphenyl-alanine (Methyldopa) reserpine and related agents on some vascular responses in the dog. J Pharmacol Exp Ther 136:80–96
Thorén P, Ricksten S-E (1979) Recordings of renal and splanchnic sympathetic nervous activity in normotensive and spontaneously hypertensive rats. Clin Sci Suppl 57 (5) 197s-199s
Trolin G (1975) Involvement of α-adrenergic receptors at different levels of the central nervous system in the regulation of blood pressure and heart rate. Acta Physiol Scand Suppl 430:1–34
Vanhoutte PM (1983) 5-hydroxytryptamine and vascular disease. Fed Proc 42:223–237
Van Nueten JM, Janssen PAJ, van Beck J, Xhonneaux R, Verbeuren TJ, Vanhoutte PM (1981) Vascular effects of ketanserin (R 41468), a novel antagonist at 5-HT2-receptors. J Pharmacol Exp Ther 218:217–230
Weiss L (1974) Aspects of the relation between functional and structural cardiovascular factors in primary hypertension. Acta Physiol Scand Suppl 409:1–58
Department of Pharmacology, University of Göteborg, Box 33031, S-400 33, Göteborg, Sweden
Anders Pettersson, Bengt Persson, Matts Henning & Thomas Hedner
Pettersson, A., Persson, B., Henning, M. et al. Antihypertensive effects of chronic 5-hydroxytryptamine (5-HT2) receptor blockade with ketanserin in the spontaneously hypertensive rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 327, 43–47 (1984). https://doi.org/10.1007/BF00504990
Received: 02 December 1983
Accepted: 20 March 1984
Issue Date: March 1984
DOI: https://doi.org/10.1007/BF00504990
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4